tiprankstipranks
Advertisement
Advertisement

RGNX Stock Latest News

Regenxbio price target raised to $18 from $16 at Morgan Stanley
The FlyRegenxbio price target raised to $18 from $16 at Morgan Stanley
2d ago
RGNX
Regenxbio downgraded to Equal Weight from Overweight at Barclays
PremiumThe Fly
Regenxbio downgraded to Equal Weight from Overweight at Barclays
2d ago
RGNX
Regenxbio reports Q2 EPS 43c vs. ($1.38) last year
PremiumThe Fly
Regenxbio reports Q2 EPS 43c vs. ($1.38) last year
3d ago
RGNX
RegenXBio Inc. (RGNX) Q2 Earnings Cheat Sheet
PremiumPre-Earnings
RegenXBio Inc. (RGNX) Q2 Earnings Cheat Sheet
5d ago
RGNX
RegenXBio Inc. (RGNX) Q2 Earnings Cheat Sheet
PremiumPre-Earnings
RegenXBio Inc. (RGNX) Q2 Earnings Cheat Sheet
6d ago
RGNX
RegenXBio Raises Capital Through Public Equity Offering
PremiumCompany AnnouncementsRegenXBio Raises Capital Through Public Equity Offering
20d ago
8K
RGNX
Regenxbio presents long-term data for surabgene lomparvovec
Premium
The Fly
Regenxbio presents long-term data for surabgene lomparvovec
21d ago
RGNX
Midday Fly By: Netflix forecast fuels fears, SpaceX tumbles after scrubbing test
Premium
The Fly
Midday Fly By: Netflix forecast fuels fears, SpaceX tumbles after scrubbing test
23d ago
AA
BP
Regenxbio 10M share Spot Secondary priced at $9.00
PremiumThe Fly
Regenxbio 10M share Spot Secondary priced at $9.00
23d ago
RGNX
Regenxbio announces $100M common stock offering
PremiumThe Fly
Regenxbio announces $100M common stock offering
24d ago
RGNX
RegenXBio: Advancing Gene Therapy Pipeline and De-Risking Milestones Support Buy Rating and Unchanged $26 Price Target
PremiumRatings
RegenXBio: Advancing Gene Therapy Pipeline and De-Risking Milestones Support Buy Rating and Unchanged $26 Price Target
1M ago
RGNX
Regenxbio Advances Diabetic Retinopathy Gene Therapy Trial
PremiumCompany Announcements
Regenxbio Advances Diabetic Retinopathy Gene Therapy Trial
1M ago
8K
RGNX
Regenxbio says first patient dosed in Phase IIb/III NAAVIGATE trial
PremiumThe FlyRegenxbio says first patient dosed in Phase IIb/III NAAVIGATE trial
1M ago
ABBV
RGNX
RegenXBio: Advancing Late-Stage RGX-202 and Navsunli Programs Underpin Buy Rating, $16 Price Target Maintained
Premium
Ratings
RegenXBio: Advancing Late-Stage RGX-202 and Navsunli Programs Underpin Buy Rating, $16 Price Target Maintained
2M ago
RGNX
Regenxbio completes dosing in confirmatory study of RGX-202
Premium
The Fly
Regenxbio completes dosing in confirmatory study of RGX-202
2M ago
RGNX
Regenxbio price target raised to $32 from $27 at Baird
PremiumThe Fly
Regenxbio price target raised to $32 from $27 at Baird
2M ago
RGNX
H.C. Wainwright notes Regenxbio doesn’t need more studies for BLA resubmission
PremiumThe Fly
H.C. Wainwright notes Regenxbio doesn’t need more studies for BLA resubmission
2M ago
RGNX
Morning Movers: Getty Images skyrockets after OpenAI deal
PremiumThe Fly
Morning Movers: Getty Images skyrockets after OpenAI deal
2M ago
ACA
APGE
Video: SpaceX dips after notes offering, KeyBanc initiation
PremiumThe Fly
Video: SpaceX dips after notes offering, KeyBanc initiation
2M ago
ACA
CRH
Regenxbio aligns with FDA on path forward for Navsunli
PremiumThe FlyRegenxbio aligns with FDA on path forward for Navsunli
2M ago
RGNX
Regenxbio up 25% after saying FDA will reverse rejection, consider application
Premium
The Fly
Regenxbio up 25% after saying FDA will reverse rejection, consider application
2M ago
RGNX
Regenxbio tells WSJ that FDA will reverse rejection of drug
Premium
The Fly
Regenxbio tells WSJ that FDA will reverse rejection of drug
2M ago
QURE
REPL

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >